These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 14523284)

  • 21. 30 years after HIV identification: where to from here?
    Stover J
    Expert Rev Anti Infect Ther; 2011 Nov; 9(11):947-9. PubMed ID: 22029511
    [No Abstract]   [Full Text] [Related]  

  • 22. [HIV-1 protease inhibitors: cell metabolism and drug resistance (review)].
    Bobkova MR
    Ter Arkh; 2008; 80(10):77-80. PubMed ID: 19105421
    [No Abstract]   [Full Text] [Related]  

  • 23. [Inappropriate combinations of antiretroviral drugs].
    Machala L; Cerný R
    Klin Mikrobiol Infekc Lek; 2004 Oct; 10(5):241-3. PubMed ID: 15558454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HAART breaks: structured treatment interruptions.
    Grinberg L
    Focus; 2000 Sep; 15(10):5-6. PubMed ID: 12182145
    [No Abstract]   [Full Text] [Related]  

  • 25. Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status.
    Kwara A; Flanigan TP; Carter EJ
    Int J Tuberc Lung Dis; 2005 Mar; 9(3):248-57. PubMed ID: 15786886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predicting differential responses to structured treatment interruptions during HAART.
    Bajaria SH; Webb G; Kirschner DE
    Bull Math Biol; 2004 Sep; 66(5):1093-118. PubMed ID: 15294419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baseline antiretroviral resistance and clinical outcomes in an urban HIV clinic.
    Klibanov OM; Dolder CR; Assefa F; Ekwonu TJ
    AIDS Patient Care STDS; 2013 Apr; 27(4):205-7. PubMed ID: 23514132
    [No Abstract]   [Full Text] [Related]  

  • 28. Starting highly active antiretroviral therapy: why, when and response to HAART.
    Mocroft A; Lundgren JD
    J Antimicrob Chemother; 2004 Jul; 54(1):10-3. PubMed ID: 15163656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions.
    Metzner KJ; Bonhoeffer S; Fischer M; Karanicolas R; Allers K; Joos B; Weber R; Hirschel B; Kostrikis LG; Günthard HF;
    J Infect Dis; 2003 Nov; 188(10):1433-43. PubMed ID: 14624368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes.
    De Luca A; Vendittelli M; Baldini F; Di Giambenedetto S; Trotta MP; Cingolani A; Bacarelli A; Gori C; Perno CF; Antinori A; Ulivi G
    Antivir Ther; 2004 Aug; 9(4):583-93. PubMed ID: 15456090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SP-01A helps with quality of life.
    AIDS Patient Care STDS; 2008 Feb; 22(2):160-1. PubMed ID: 18273942
    [No Abstract]   [Full Text] [Related]  

  • 32. Strategies for the scale-up of antiretroviral therapy in South Africa through health system optimization.
    Barker PM; McCannon CJ; Mehta N; Green C; Youngleson MS; Yarrow J; Bennett B; Berwick DM
    J Infect Dis; 2007 Dec; 196 Suppl 3():S457-63. PubMed ID: 18181694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection.
    Streeck H; Jessen H; Alter G; Teigen N; Waring MT; Jessen A; Stahmer I; van Lunzen J; Lichterfeld M; Gao X; Allen TM; Carrington M; Walker BD; Rockstroh JK; Altfeld M
    J Infect Dis; 2006 Sep; 194(6):734-9. PubMed ID: 16941338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of time to undetectable HIV viral load in the first 16 weeks after the start of three and four antiretroviral regimens.
    Manavi K; Scott G
    Int J STD AIDS; 2006 Aug; 17(8):522-4. PubMed ID: 16925897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. When to start antiretroviral therapy--ready when you are?
    Sax PE; Baden LR
    N Engl J Med; 2009 Apr; 360(18):1897-9. PubMed ID: 19339713
    [No Abstract]   [Full Text] [Related]  

  • 36. HIV/AIDS in 2004: the epidemiologist's point of view.
    Girardi E; Lauria FN; Ippolito G
    Cell Death Differ; 2005 Aug; 12 Suppl 1():837-44. PubMed ID: 15776000
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment of infants coinfected with HIV-1 and cytomegalovirus with combination antiretrovirals and ganciclovir.
    Saitoh A; Viani RM; Schrier RD; Spector SA
    J Allergy Clin Immunol; 2004 Oct; 114(4):983-5. PubMed ID: 15480350
    [No Abstract]   [Full Text] [Related]  

  • 38. Antiretroviral reduction: is it time to rethink the unthinkable?
    Colasanti J; Marconi VC; Taiwo B
    AIDS; 2014 Apr; 28(7):943-7. PubMed ID: 24401641
    [No Abstract]   [Full Text] [Related]  

  • 39. Antiretroviral Therapy.
    Brock JB; Henderson H
    J Miss State Med Assoc; 2015 Jun; 56(6):166, 171-2. PubMed ID: 26242056
    [No Abstract]   [Full Text] [Related]  

  • 40. Structured treatment interruption for patients with human immunodeficiency virus infection.
    Roca B
    N Engl J Med; 2003 Dec; 349(23):2268-9; author reply 2268-9. PubMed ID: 14657438
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.